Clinical testing of Boron neutron capture therapy (BNCT), a new-generation radiation treatment pioneered in Finland, has been proved to be effective in advanced head and neck cancer. The BNCT-based treatment has been successfully used to treat patients who have not responded to previous treatments and generally have poor prognosis, according to Boneca Corporation, the world’s only provider of radiation safety-audited BNCT treatment.
Biologically targeted BNCT treatment is based on producing radiation inside a tumour using boron-10 and thermal neutrons, while keeping the impact of radiation on surrounding healthy tissue to a minimum. BNCT treatment has been given to over 200 patients to date, the majority of whom had recurred head and neck cancer or malignant brain tumour. Approximately 6% of patients have come from abroad as a result of international interest in BNCT.
“We have sufficient capacity to treat more patients and are very interested in collaborating with hospitals outside Finland that would like to offer the option of BNCT treatment for their patients,” says Boneca’s CEO, Markku Pohjola.
Boneca works closely with the Department of Oncology at the Helsinki University Central Hospital, and treatment-related decisions are taken jointly with the hospital’s otolaryngology, radiation therapy and oncology specialists. Boneca is responsible for administering the treatment, which is given at a special facility adjacent to the research nuclear reactor used at the VTT Technical Research Centre of Finland.
Boneca is based at the main campus of Helsinki University Central Hospital and is owned by Clinical Research Institute HUCH Ltd, Sitra, Finnish Innovation Fund, and VTT Ventures Ltd.
Source: Boneca Corporation